GLAP, glyceraldehyde-derived pyridinium-type advanced glycation end product (AGE), formed by glyceraldehyde-related glycation, was identified in the plasma protein and the tail tendon collagen of streptozotocin (STZ)-induced diabetic rats. It was detected in the plasma protein and the collagen in diabetic rats by LC-MS and LC-MS/MS analysis, but was not detected in normal rats. In addition, GLAP was formed from glyceraldehyde-3-phosphate (GA3P) with lysine as well as glyceraldehyde (GLA) with lysine in vitro. Accordingly, it is suggested that an increase in the GLAP level reflects an increase in the GLA level and the GA3P level. GLAP might be a biomarker for reduced activity of the glyceraldehyde-related enzymes in the metabolic diseases such as diabetic complications.
GLAP, glyceraldehyde-derived pyridinium-type advanced glycation end product (AGE), formed by glyceraldehyde-related glycation, was identified in the plasma protein and the tail tendon collagen of streptozotocin (STZ)-induced diabetic rats. It was detected in the plasma protein and the collagen in diabetic rats by LC-MS and LC-MS/MS analysis, but was not detected in normal rats. In addition, GLAP was formed from glyceraldehyde-3-phosphate (GA3P) with lysine as well as glyceraldehyde (GLA) with lysine in vitro. Accordingly, it is suggested that an increase in the GLAP level reflects an increase in the GLA level and the GA3P level. GLAP might be a biomarker for reduced activity of the glyceraldehyde-related enzymes in the metabolic diseases such as diabetic complications.
Key words: glyceraldehyde; pyridinium; glycation; Maillard reaction; advanced glycation end product
Protein is modified by carbonyl compounds in glycation (also called the Maillard reaction), and irreversible products are formed as advanced glycation end products (AGEs).
1) It is suggested that AGEs play an important role in the several chronic diseases such as diabetic complications. -Dicarbonyl and -hydroxycarbonyl compounds are formed in the degradation of sugars and in glycation, and then result in the formation of AGEs.
Proteins are modified by glyceraldehyde, which is a -hydroxycarbonyl compound. Glyceraldehyde-derived AGEs have been detected in Alzheimer's disease. 2) Additionally, they affect cell function, and show cytotoxicity. [3] [4] [5] [6] Cellular dysfunction might play an important role in the progression of diabetic complications, chronic renal failure, and neuronal diseases. We have reported that GLAP (glyceraldehyde-derived pyridinium compound) is a novel glyceraldehyde-derived AGE 7) that induces oxidative cellular dysfunction.
8)
However, it is not still clear whether GLAP is actually formed in the living body. In this study, we report the detection and determination of GLAP in the plasma protein and the tail tendon collagen obtained from streptozotocin (STZ)-induced diabetic rats.
Materials and Methods
Chemicals. Glyceraldehyde, glycolaldehyde, methylglyoxal, glucose, fructose, N -acetyl-L-lysine, and bovine serum albumin (BSA) were obtained from SigmaAldrich (St. Louis, MO). Streptozotocin (STZ), mannose, arabinose, xylose, trichloroacetic acid (TCA), trifluoroacetic acid (TFA), heptafluoro-n-butyric acid (HFBA), glucose CII test, and Ninhydrin Reagent-835 Set were from Wako Pure Chemical (Osaka, Japan). Ribose was from Tokyo Chemical (Tokyo). Acetonitrile (HPLC grade) and methanol (HPLC grade) were from Kanto Chemical (Tokyo), and all other chemicals used in this study were of analytical reagent grade. Water was used after purification by reverse osmosis, using Milli RO 10PLUS (Millipore, Billerica, MA), and further treated Simpli Lab-UV (Millipore).
Purification of GLAP. GLAP was purified by prepay To whom correspondence should be addressed. Fax: +81-44-934-7902; E-mail: fumi@isc.meiji.ac.jp Abbreviations: AGE, advanced glycation end products; BSA, bovine serum albumin; CML, carboxymethyllysine; 3DG, 3-deoxyglucosone; GA3P, glyceraldehyde-3 phosphate; GAPDH, glyceraldehyde-3 phosphate dehydrogenase; GLAP, glyceraldehyde-derived pyridinium compound; HFBA, heptafluolo-n-butylic acid; MG-H1, methylglyoxal-derived hydroimidazolone; MGO, methylglyoxal; STZ, streptozotocin; TCA, trichloroacetic acid; TFA, trifluoroacetic acid rative HPLC as previously described, 8) and hydrolyzed with 2 N HCl for deacetylation. Briefly, glyceraldehyde (200 mM) and N -acetyllysine (100 mM) were dissolved in 200 mM sodium phosphate buffer (pH 7.4) and incubated at 37 C for one week. The reaction mixture was filtered with a cellulose acetate membrane filter unit (DISMIC, 0.20 mm, Advantec, Tokyo), and then put on an mBondasphere C 18 column (150 Â 19 mm I.D., Waters, Milford, MA) on preparative reversed phase HPLC. The sample was eluted with isocratic of 25 mM sodium phosphate buffer (pH 7.0) from 0 to 65 min and a linear gradient of 0-40% acetonitrile containing 25 mM sodium phosphate buffer (pH 7.0) from 65 to 90 min at a flow rate of 4 ml/min. A major peak containing GLAP was collected using a fraction collector and lyophilized as GLAP (N-acetyl form). For hydrolysis, GLAP (Nacetyl form, 1 mg) was put in a small glass tube, and the tube was put in a sealed vial with 2 N HCl (0.1 ml) under an N 2 atmosphere. The vial was heated at 105 C for 2 h. The hydrolyzed sample was dissolved in water and put on a Cosmosil C 18 column (250 Â 4:6 mm I.D., Nacalai Tesque, Kyoto, Japan), which had been equilibrated with 0.05% trifluoroacetic acid (TFA). The sample was eluted with 0.05% TFA. Then the GLAP fractions were collected and lyophilized. The GLAP was dissolved in water and adjusted to each concentration. The GLAP concentration was determined by ninhydrin assay with leucine as standard.
Carbonyl-modified protein. Glycated protein (carbonyl-modified protein) was prepared by a method previously described. 8) Briefly, bovine serum albumin (BSA, 10 mg/ml) was dissolved in 200 mM sodium phosphate buffer (pH 7.4) and incubated with 100 mM carbonyls (glyceraldehyde, methylglyoxal, glyoxal, fructose, ribose, xylose, glucose, and mannose) or 10 mM glycolaldehyde at 37 C for one week or 4 weeks (glucose). The mixtures were dialyzed against PBS and water. Finally, carbonyl-modified proteins were lyophilized and stored below À20 C until analysis.
Diabetic rats. This experiment was conducted in accordance with the Guidelines for Animal Experimentation No. 6, established by the Prime Minister's Office of Japan in 1980, and the Guidelines of the Faculty of Agriculture of Meiji University.
Sprague-Dawley (SD) rats (male, 6 weeks old, SPF) were obtained from Charles River Japan. The animals were housed in stainless-steel cages with water ad libitum, and maintained in 23 AE 2 C under a constant light-dark (12 h:12 h) cycle. After 24 h, the rats were randomized into two groups (the diabetic and control groups). Group 1 (diabetic) rats were anesthetized with diethylether, and 65 mg/kg of streptozotocin (STZ, 50 mM sodium citrate buffered solution, pH 4.5) was injected into the abdominal cavity. Group 2 (control) rats were injected with sodium citrate buffed solution in the same manner. The animals were kept on a standard diet (MF, Oriental Yeast, Tokyo) and water ad libitum for 12 weeks.
Subsequently, the animals were anesthetized with diethylether, and blood samples were obtained from the abdominal vein with heparin as anticoagulant. Plasma was harvested after centrifugation (2,500 rpm, 10 min) and plasma glucose was measured by the glucose CII test. The plasma samples were stored at À20 C until use. Additionally, the tail tendon was collected and defatted with acetone. The samples were used as collagen samples, and were stored at À20 C until analysis.
Hydrolysis and solid extraction. Plasma samples (0.5 ml) were combined with an equal volume of 10% trichloroacetic acid (TCA, 0.5 ml), and gently mixed. The mixture was centrifuged at 3,000 rpm for 10 min. The pellet was washed with diethylether and then dried as crude proteins. The crude protein samples and the collagen samples (1 mg) were hydrolyzed with 6 N HCl at 105
C for 20 h. Hydrolyzed samples were dissolved in 20 mM sodium citrate buffer (pH 4.5) and put on a OASIS-MCX extraction cartridge (Waters) which had been equilibrated with the same solution. The cartridge was washed with 80% acetonitrile and then eluted with 2 N HCl. The solvent was removed under reduced pressure. Subsequently, the samples were dissolved in 0.05% heptafluoro-n-butyric acid (HFBA) solution and put on a Sep-Pak C 18 cartridge (Waters) which had been equilibrated with the same solution. The samples were fractionated with 0.05% HFBA and then 20% methanol. The 20% methanol fractions were collected, and the solvent was removed under reduced pressure. The residue was dissolved with 0.005% HFBA and filtered with a cellulose acetate membrane filter unit (DISMIC, 0.45 mm, Advantec) for LC-MS and LC-MS/MS analysis.
LC-MS. LC-MS analysis was done by the ESI-MS system (Mariner, Applied Biosystems, Foster City, CA) and the connecting HPLC system (Agilent, Santa Clara, CA). A 5-ml sample was put on a Develosil C30-UG column (250 Â 2:0 mm I.D., Nomura Chemical, Aichi, Japan), and eluted with a linear gradient of 0.005% HFBA-60% acetonitrile from 0 to 20 min at a flow rate of 0.2 ml/min. The column temperature was ambient. Ionization was carried on electrospray ionization (ESI) under the positive polarity condition. GLAP was detected as a precursor ion at m=z 255 [M þ ] on selected ion monitoring (SIM). Fluorescence HPLC. Carbonyl-modified proteins were analyzed by reversed phase HPLC using a fluorescence detector. Protein samples (1 mg/ml) were hydrolyzed with 6 N HCl at 105 C for 20 h. Hydrolyzed samples were dissolved in 0.1% HFBA solution and put on a Sep-Pak C 18 cartridge which had been equilibrated with the same solution. The sample was fractionated with 0.1% HFBA and then 20% methanol. The 20% methanol fractions were collected, and the solvent was removed under reduced pressure. The residue was dissolved in 0.1% HFBA and filtered with a cellulose acetate membrane filter unit. The filtrate was put on a Cosmosil C 18 column (4:6 Â 250 mm I.D., Nacalai Tesque, Kyoto, Japan), and eluted with linear gradient of 0.05% HFBA-60% CH 3 CN from 0 to 120 min at a flow rate of 1 ml/min. GLAP was measured by reversed phase HPLC with a fluorescence detector (ex. 298 nm, em. 388 nm).
LC-MS/MS. LC-MS/MS
GA3P-derived GLAP. Lysine (10 mM) was dissolved in 200 mM phosphate buffer (pH 7.4) and incubated with GA3P (20 mM) or GLA (10 mM) at 37 C for 24 h. The mixture was analyzed by LC-MS.
Apparatus. Amino acid analysis was performed by the Pico-Tag system (Waters), which is consisted of a Statistical analysis. Data were expressed as the means AE SD. The statistical significance of differences was established by one-way analysis of variance (ANOVA), Dunnett's test, and Student's t test using the JMP 4.0.5J microcomputer program (SAS Institute, Cary, NC). Differences with probability values less than 5% were considered significant.
Results and Discussion
GLAP (glyceraldehyde-derived pyridinium compound) is a glyceraldehyde-derived advanced glycation end product (AGE), formed from glyceraldehyde with lysine residue in protein. The present study investigated the detection and determination of GLAP in streptozotocin (STZ)-induced diabetes rats. Figures 1 and 2 show the typical elution profile of GLAP on LC-MS analysis. As shown in Fig. 1 , GLAP was detected in the plasma protein from diabetic rats (1A), but was not detected in normal rats (1B). Figure 2 shows the detection of GLAP in tail tendon collagen of diabetic rats. GLAP was also detected in collagen from diabetic rats (2A), but was not detected in normal rats (2B). Identification of GLAP was verified by LC-MS/MS analysis, as shown in Fig. 3 . GLAP was detected as the m=z 255 (M þ ) ion in the plasma protein of diabetic rats (Fig. 3A) , and the fragment ion was observed at m=z 130, 126, and 84 (Fig. 3B) . Determination data are summarized in Table 1 . Weight and plasma glucose level of diabetes were significantly different from the control on Student's t test at p < 0:05. The GLAP level increased in diabetes, but was not detected in normal rats.
Subsequently, the GLAP level was analyzed by fluorescence HPLC in carbonyl-modified proteins using bovine serum albumin (BSA) as model protein. A typical elution profile is shown in Fig. 4 . As shown in Table 2 , GLAP was formed only in the glyceraldehydemodified albumin, not in the other carbonyls (glyceraldehyde, glycolaldehyde, methylglyoxal, glyoxal, fructose, ribose, xylose, glucose, and mannose). Glyceraldehyde was probably generated from sugars such as glucose by the incubation procedure, but GLAP was not detected in the sugar-modified albumin. The GLAP level might have been very low in each sugar-modified albumin. The present study suggests that GLAP is a specific AGE formed by glyceraldehyde-related glycation.
The proposed pathway of GLAP formation is shown in Fig. 5 . The lysine residue adducts to the carbonyl A, GLAP was detected as precursor ion at m=z 255 and product ion at m=z 130 on selected ion monitoring; B, Mass spectrum of a peak at R.T. 4.5 min. GLAP was formed from glycelaldehyde (GLA) with lysine. As Fig. 6 shows, GLAP was formed from glyceraldehyde-3 phosphate (GA3P) with lysine ( Fig. 6B) , as well as by GLA with lysine (Fig. 6A) . GLAP was also formed from GA3P, a key intermediate of the glycolic pathway. The degradation of GA3P is a key pathway in glyceraldehyde formation. Accordingly, it is suggested that an increase in the GLAP level reflects an increase in the GLA level and the GA3P level. GLAP might be increased by reduced activity of a glyceraldehyde-related enzyme, such as GA3P dehydrogenase (GAPDH).
AGEs are nonenzymatic chemical modifications of in vivo proteins that can serve as biomarkers of carbonyl and oxidative stresses resulting from sugar and lipid oxidation. For example, pentosidine 9) and carboxymethyllysine (CML) 10) are markers of glycoxidation. Pyrraline, 11) pyrropyridine, 12) and imidazolones are from 3-deoxyglucosone (3DG)-modified proteins.
13) Addi- tionally, MG-H1 [14] [15] [16] serves as an index of injury to glyceraldehyde and methylglyoxal-related enzymes in glycolysis. Since GLAP is not formed from MGO, GLAP might serves as a specific marker of reduced activity of a glyceraldehyde-related enzyme (such as GAPDH) in metabolic diseases such as diabetic complications. 
